Wolverine
BPC-157 + TB-500
In short
- BPC-157 plus TB-500 — the most widely used repair blend, on the theory that the two act on complementary parts of tissue repair.
- The rationale is genuine: BPC-157 is associated with angiogenesis, TB-500 with cell migration. Whether that complementarity produces anything in humans is untested.
- Neither component has meaningful human efficacy evidence, so the blend combines two unproven things.
- The WADA status DIFFERS between components — TB-500 is explicitly prohibited at all times, BPC-157 currently is not. The blend is therefore prohibited.
- Both components share a theoretical angiogenesis-related concern, so combining them compounds it rather than balancing it.
Structure
A blend of two peptides rather than a single molecule, so there is no combined structure. See the BPC-157 and TB-500 entries for their individual structures.
How it works
BPC-157 is associated in preclinical work with angiogenesis via the nitric oxide system and VEGFR2 upregulation. TB-500 is a thymosin beta-4 fragment associated with actin regulation and cell migration.
The combination rationale is that repair requires both a blood supply and cells arriving to do the work, so pairing an angiogenic agent with a migration-promoting one should be additive.
That is a reasonable story. It is also a story — no study has tested whether the combination outperforms either component, in any species.
What the research shows
No study has tested this specific combination in humans. Whatever evidence exists belongs to the individual components, tested individually.
BPC-157's human evidence is three small pilot studies. TB-500's fragment has no human trials at all; the relevant human work concerns full-length thymosin beta-4 and did not lead to approval.
Community reports of recovery are abundant, uncontrolled, and confounded by the natural history of injuries that improve regardless.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
No published dosing data for this compound.
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly reported combined daily dosing | 250–500 µg BPC-157 with 2–5 mg TB-500 weekly | subcutaneous |
No study has tested this specific combination in humans. Whatever evidence exists belongs to the individual components, tested individually. A pre-mixed vial fixes the ratio between components at whatever the vendor chose. You can change the total volume you draw, but you cannot change the proportions — so if one component suits you at a different relative amount, a blend cannot express that. Buying components separately costs more vials and buys back that control. The typical 5 mg / 5 mg vial implies equal amounts, but the components are usually dosed on very different schedules — BPC-157 daily, TB-500 weekly — which a single pre-mixed vial cannot accommodate.
Handling and storage
Supplied as a lyophilised powder requiring reconstitution with bacteriostatic water. The powder is comparatively stable; once reconstituted it is refrigerated and used within weeks. Track the date you reconstitute each vial — the Inventory section does this, and it is the difference between knowing a vial is three weeks old and guessing.
One reconstitution and one injection for both components is the practical appeal. Note the scheduling mismatch above: the conventional protocols for these two compounds run on different frequencies, and a blend forces them onto the same one.
Side effects
Injection-site reactions are the most commonly reported issue, as for either component alone.
The consideration worth understanding is that both components are proposed to promote angiogenesis and, for TB-500, cell migration. Those are two of the processes tumours depend on. Neither has been shown to cause harm in humans, and neither has been shown not to — combining them stacks the same theoretical concern rather than offsetting it.
Combinations
Running components together makes attribution impossible in both directions. If something improves you cannot tell which component did it, and if something goes wrong you cannot tell which one to stop. Blends are convenient and they are also the format that teaches you least about your own response.
Research status
The components have separate preclinical literatures, described in their own entries. The combination has none.
Its popularity derives from community practice and vendor packaging rather than from any study of the pair.
Legal status
Neither component is approved in any jurisdiction. Sold for research use only. BPC-157 was placed in the FDA's Category 2 bulk substances list in 2023, and thymosin beta-4 appears in the same category.
WADA status
PROHIBITED. TB-500 is explicitly prohibited at all times under WADA class S2. That makes the blend prohibited regardless of BPC-157's separate status, which is currently not listed. A tested athlete taking this blend is taking a named prohibited substance.
Conclusion
Wolverine is the most popular blend in this library and combines two compounds neither of which has demonstrated efficacy in humans.
The mechanistic story is coherent and the evidence for it does not exist. If you use it, the WADA status is the one hard fact worth acting on.
Sources
Track your own Wolverine protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.